Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (104-week) improvement in fatigue in patients with psoriatic arthritis: Pooled results from 3 phase III, randomized, controlled trials

Phase Iii ◽

Controlled Trials ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

FRI0470 Long-Term (156-Week) Safety Profile of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Safety Analysis of 3 Phase III, Randomized, Controlled Trials

10.1136/annrheumdis-2016-eular.3265 ◽

2016 ◽

Vol 75 (Suppl 2) ◽

pp. 608.1-608

Author(s):

P.J. Mease ◽

D.D. Gladman ◽

J.J. Gomez-Reino ◽

S. Hall ◽

A. Kavanaugh ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Safety Profile ◽

Safety Analysis ◽

Phase Iii ◽

Controlled Trials ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

O03 Apremilast, an Oral Phosphodiesterase-4 Inhibitor, is Associated with Long-Term (104-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Results from Three Phase III Randomized Controlled Trials

Rheumatology ◽

10.1093/rheumatology/kew122.002 ◽

2016 ◽

Keyword(s):

Psoriatic Arthritis ◽

Phase Iii ◽

Controlled Trials ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

Three Phase ◽

194 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-Term (104 Week) Improvement in Fatigue in Patients with Psoriatic Arthritis: Pooled Results from Three Phase III Randomized Controlled Trials

Rheumatology ◽

10.1093/rheumatology/kew145.005 ◽

2016 ◽

Keyword(s):

Psoriatic Arthritis ◽

Phase Iii ◽

Controlled Trials ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

Three Phase ◽

FRI0512 Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (156-week) improvements in basdai in psoriatic arthritis patients: pooled results from 3 phase iii, randomized, controlled trials

10.1136/annrheumdis-2017-eular.3299 ◽

2017 ◽

Author(s):

PJ Mease ◽

H Marzo-Ortega ◽

A Poder ◽

F Van den Bosch ◽

J Wollenhaupt ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Phase Iii ◽

Controlled Trials ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

THU0432 Apremilast, An Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (104-Week) Improvement in Fatigue in Patients with Psoriatic Arthritis: Pooled Results from 3 Phase III, Randomized, Controlled Trials

10.1136/annrheumdis-2016-eular.1487 ◽

2016 ◽

Vol 75 (Suppl 2) ◽

pp. 346.1-346

Author(s):

A. Kavanaugh ◽

D.D. Gladman ◽

C.J. Edwards ◽

A. Poder ◽

F. Lioté ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Phase Iii ◽

Controlled Trials ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

THU0420 Apremilast, An Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvements in BASDAI in Patients with Psoriatic Arthritis: Pooled Results from 3 Phase III, Randomized, Controlled Trials

10.1136/annrheumdis-2016-eular.2400 ◽

2016 ◽

Vol 75 (Suppl 2) ◽

pp. 341.1-341

Author(s):

P. Mease ◽

H. Marzo-Ortega ◽

A. Poder ◽

F. Van den Bosch ◽

J. Wollenhaupt ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Phase Iii ◽

Controlled Trials ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

THU0432 Long-Term (104-Week) Safety Profile of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, In Patients with Psoriatic Arthritis: Pooled Safety Analysis of Three Phase 3, Randomized, Controlled Trials

10.1136/annrheumdis-2015-eular.3582 ◽

2015 ◽

Vol 74 (Suppl 2) ◽

pp. 355.3-356 ◽

Cited By ~ 1

Author(s):

P. Mease ◽

A. Adebajo ◽

D. Gladman ◽

J. Gomez-Reino ◽

S. Hall ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Safety Profile ◽

Controlled Trials ◽

Phase 3 ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

Three Phase ◽

OP0078 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-Term (52-WEEK) Improvement in Measures of Disease Activity in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials

10.1136/annrheumdis-2014-eular.1827 ◽

2014 ◽

Vol 73 (Suppl 2) ◽

pp. 90.2-91 ◽

Cited By ~ 1

Author(s):

A. Kavanaugh ◽

M. Cutolo ◽

P. Mease ◽

D. Gladman ◽

A. Adebajo ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Disease Activity ◽

Controlled Trials ◽

Phase 3 ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

SAT0408 Long-Term Safety and Tolerability of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Safety Analysis of Three Phase 3, Randomized, Controlled Trials

10.1136/annrheumdis-2014-eular.5589 ◽

2014 ◽

Vol 73 (Suppl 2) ◽

pp. 742.2-743 ◽

Cited By ~ 3

Author(s):

P.J. Mease ◽

A. Kavanaugh ◽

D. Gladman ◽

A.O. Adebajo ◽

J.J. Gomez-Reino ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Safety Analysis ◽

Controlled Trials ◽

Phase 3 ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

Three Phase ◽

OP0169 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-Term (104-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Results from Three Phase 3, Randomized, Controlled Trials

10.1136/annrheumdis-2015-eular.3594 ◽

2015 ◽

Vol 74 (Suppl 2) ◽

pp. 133-134 ◽

Cited By ~ 3

Author(s):

D. Gladman ◽

A. Kavanaugh ◽

A. Adebajo ◽

J. Gomez-Reino ◽

J. Wollenhaupt ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Controlled Trials ◽

Phase 3 ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

Three Phase ◽